Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mosunetuzumab - Genentech

Next Previous
Drug Profile

Mosunetuzumab - Genentech

Alternative Names: Anti-CD20/CD3 T-cell dependent bispecific antibody; BTCT 4465A; CD20-TBD; CD20xCD3 T-cell engaging bispecific antibody; Lunsumio; Lunsumio VELO; mosunetuzumab-axgb; RG7828; RO7030816

Latest Information Update: 27 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma
  • Registered Non-Hodgkin's lymphoma
  • Preregistration Diffuse large B cell lymphoma
  • Phase II Marginal zone B-cell lymphoma; Systemic lupus erythematosus
  • Phase I/II Chronic lymphocytic leukaemia
  • No development reported B-cell lymphoma

Most Recent Events

  • 05 Aug 2026 Roche plans to submit regulatory application in Systemic lupus erythematosus in 2029 or beyond (Roche pipeline, August 2026)
  • 18 Jun 2026 US FDA assigns PDUFA action date of (09/02/2027) for Mosunetuzumab for Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) (SC)
  • 18 Jun 2026 US FDA accepts sBLA for Mosunetuzumab for Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) for review in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top